Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Eupraxia Pharmaceuticals Inc T.EPRX

Alternate Symbol(s):  T.EPRX.WT | EPRX | T.EPRX.WT.A

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company’s proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of... see more

Current News (TSX:EPRX)

Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

GlobeNewswire November 13, 2025

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

GlobeNewswire November 4, 2025

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

GlobeNewswire September 29, 2025

Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option

GlobeNewswire September 24, 2025

Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

GlobeNewswire September 22, 2025

Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares

GlobeNewswire September 22, 2025

First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI

GlobeNewswire September 2, 2025

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 12, 2025

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

GlobeNewswire July 22, 2025
View More News ››

Opinion & Analysis (TSX:EPRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:EPRX)

Webinar Recap w EPRX CEO James Helliwell & CFO Alex Rothwell

<< View Post To Watch Video >>
bmreed - May 20, 2025

Rename company from "Eupraxia" to "DiffuSphere"

The DiffuSphere opportunity across indications (cancer, arthritis, etc.) is so huge that EPRX does itself a great disservice by focusing...
sprintingtrader - May 16, 2025

Live Webinar: EPRX CEO James Helliwell - Tue May 13 @ 2PM ET

Live Webinar with Eupraxia Pharmaceuticals $EPRX CEO James Helliwell Tuesday, May 13th at 2PM ET / 11AM PT Q&A with Radius...
bmreed - May 8, 2025

Webinar Recap: $EPRX CEO James Helliwell & CFO Alex Rothwell

<< View Post To Watch Video >>
bmreed - February 28, 2025

RE:Live Webinar w $EPRX CEO James Helliwell & CFO Alex Rothwell

CEO James Helliwell and new CFO, Alex Rothwell, will be discussing Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for...
bmreed - February 25, 2025

Live Webinar w $EPRX CEO James Helliwell & CFO Alex Rothwell

Live Webinar - Eupraxia Pharmaceuticals $EPRX CEO James Helliwell and CFO Alex Rothwell Wednesday, February 26th at 2pm ET / 11am PT ...
bmreed - February 24, 2025
View more Bullboard ››

Lomiko Metals Inc.

Lomiko Metals Inc.

Lomiko Metals Inc. is a Canada-based company developing its flagship graphite property, La Loutre graphite in southern Quebec ...
View More »